Drug Discovery News and Research

RSS

The drug discovery process begins with recognizing a disease or clinical condition in which there is a lack of adequate medical treatment. Once a potential drug has been identified, pre-clinical research can begin. This process includes several stages; the first of which involves identifying and validating the prospective drug’s target through assay development, high throughput screening, hit identification and finally, lead optimization. Once the pre-clinical process is complete, the newly synthesized drug candidate is selected for future clinical development.

Researchers advocate local data strategies for early cancer detection

Researchers are calling for the application of locally driven strategies, supported by stronger regional evidence, to improve early cancer detection and precise care.

22 Jun 2026

New human protein atlas maps how cancer rewires the body’s tissues

Researchers created a DIA-MS atlas of 13,609 proteins across 2,856 samples from fetal, healthy adult, paired non-tumor, and tumor tissues. The resource maps tissue-specific protein patterns, cancer-associated changes, organ-specific drug-toxicity signals, and candidate therapeutic targets.

21 Jun 2026

AI discovers hidden antibiotic candidates inside disease-causing prions

New antibiotic candidates for drug-resistant bacteria may reside inside prions, mis-folded protein in the brain best known for rare and fatal degenerative brain diseases.

19 Jun 2026

Accelerating drug discovery through AI, automation, and next-generation DMTA

Discover how AI, automation, and next-generation DMTA workflows are accelerating drug discovery with expert insights from TTP leaders.

From TTP plc 19 Jun 2026

Fish oil supplements show little benefit for Alzheimer's prevention

Americans spend more than $1 billion annually on fish oil supplements, in part due to purported cognitive benefits from the omega-3 fatty acids they contain, essential nutrients that help form brain cell connections needed for cognition.

18 Jun 2026

Insilico Medicine to showcase AI-driven drug breakthroughs at BIO 2026 International Convention

Insilico Medicine will attend the BIO 2026 International Convention, held from June 22 to 25 at the San Diego Convention Center.

18 Jun 2026

AI-designed drug for Parkinson's begins first human trial

Insilico Medicine ("Insilico", HKEX: 3696), a clinical-stage biotechnology company powered by generative artificial intelligence (AI), today announced it has achieved the first clinical milestone in its co-development collaboration with Hygtia Therapeutics with the completion of first-in-human dosing in the Phase I study of ISM8969.

17 Jun 2026

Purdue develops next-generation platform to accelerate cancer drug discovery

Researchers at the Purdue Institute for Cancer Research (PICR) have developed a next-generation technology platform designed to dramatically accelerate one of the slowest and most challenging stages of cancer drug discovery: identifying promising compounds that could eventually become new therapies.

16 Jun 2026

Researchers uncover immune loop driving Sjögren's disease progression

Sjögren's disease is a widespread chronic autoimmune disorder that attacks the body's own glands, yet its underlying disease mechanisms remain poorly understood.

10 Jun 2026

Silver nanoparticles enable precise DNA cutting and assembly

DNA is composed of long chains that act as the blueprint for living organisms. In genetic engineering, scientists cut DNA at specific sites and join the resulting fragments to other DNA sequences, enabling applications such as advanced crop breeding, genetic disease treatment, and the generation of animal models for drug discovery.

10 Jun 2026

Automated self-driving labs accelerate the search for new medicines

The Acceleration Consortium (AC) at the University of Toronto and the Structural Genomics Consortium (SGC) announced today a formalized partnership to help tackle a persistent challenge in biomedicine and early drug discovery: the development of bioactive molecules with drug-like properties, advancing our understanding of human health and disease and jump-starting new drug discovery programs.

10 Jun 2026

Houston researcher identifies new targets for fatal rhabdomyosarcoma

A cancer researcher at the University of Houston is reporting what makes malignant soft tissue cancer grow in children, identifying key mechanisms and molecular targets to prevent tumor progression in patients in future therapies of the fatal rhabdomyosarcoma.

9 Jun 2026

Webinar - Modality agnostic drug discovery strategies for data sparse targets: Lessons learned from Avammune & Cresset, hosted by Visioneers

Are you working on data-sparse or novel targets? Join us June 11th to learn how Avammune progressed from early concepts to trial-stage candidates in this space.

From Cresset 4 Jun 2026

Study potentially opens a new route to more selective cancer drug design

Researchers at the Icahn School of Medicine at Mount Sinai have identified a previously hidden druggable site in a cancer-related protein that could open the door toward the development of a new generation of more precise cancer drugs.

3 Jun 2026

New antibiotic kills drug-resistant bacteria by targeting a previously unknown vulnerability

Researchers at McMaster University have discovered a new antibiotic that kills some of the world's most dangerous and drug-resistant bacteria - and does so by targeting a previously unknown vulnerability, opening the door to an entirely new class of treatments.

3 Jun 2026

ELRIG unveils keynote speakers for Drug Discovery 2026

ELRIG, a not-for-profit, volunteer-led organization dedicated to the global drug discovery community, today announced the keynote speaker program for Drug Discovery 2026.

From ELRIG (UK) Ltd. 3 Jun 2026

Southwest Research Institute evaluates NASA's medication handling practices

Southwest Research Institute evaluated NASA's medication handling practices, which currently call for removing medications from their original packaging and storing them in resealable plastic bags.

2 Jun 2026

Introducing Evosep Proteomics to standardize and scale proteomics for research and drug development

Evosep announces the launch of Evosep Proteomics, an ecosystem designed to standardize and scale LC-MS-based proteomics for research and pharmaceutical drug development.

From Evosep 2 Jun 2026

PromptSE AI predicts drug side effects by reasoning through biological clues

PromptSE uses structured LLM prompting to generate pharmacologically relevant side-effect representations, then feeds them into deep learning models to predict drug-side effect associations. In benchmark testing, PromptSE improved prediction performance, while PromptSE+ further boosted results by adding multi-modal drug information and graph-based refinement for sparse data.

1 Jun 2026

Novel therapeutic agent proposed to combat drug resistant tuberculosis

A research team led by Associate Professor Noriyuki Kurita from the Department of Computer Science and Engineering at Toyohashi University of Technology and by Associate Professor Pornpan Pungpo from Ubon Ratchathani University in Thailand has proposed a novel therapeutic agent for tuberculosis, using high-precision molecular simulation techniques.

29 May 2026